Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)

Completed · Phase 1

Conditions studied: Age-Related Macular Degeneration

In brief

The aim of the study is to evaluate whether PF-04523655 is safe in the treatment of neovascular/wet AMD

Key facts

Study ID

NCT00725686

Run by

Quark Pharmaceuticals

People needed

54

Starts

2007-02-01

Expected to finish

2010-11-01

Last updated by the study team

2012-10-10

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient is ≥ 50 years old and in general good health. Patients with medically controlled chronic disease such as HTN, AODM, and hyperlipidemia may be included.
• Patient is capable of giving consent.
• Patient is willing and able to comply with the visit schedule and study procedures including follow-up visits.
• Patient has documented CNV secondary to AMD with evidence of active disease characterized by blood vessel leakage or evidence of hemorrhage.
• Patient has clear ocular media and adequate pupil dilation to allow good quality imaging by fundus photography.
• Patient's intraocular pressure is ≤ 25 mmHg

You may not qualify if…

• Patient is of childbearing potential. Every female patient is considered of child-bearing potential unless she has had sterilization surgery or is post-menopausal and has not had a menstrual period for at least 12 months.
• Patient has CNV due to causes other than AMD, including ocular or periocular infections.
• Patient has lesions not easily imaged and quantified.
• Patient has underlying systemic disease such as cardiac, neurological, infectious disease, uncontrolled diabetes mellitis, or disease of the eye other than AMD. Patient may have medically controlled glaucoma.
• Patient is participating in any concurrent interventional study.

Where it is running

• Pfizer Investigational Site — Beverly Hills, California, United States
• Pfizer Investigational Site — Pasadena, California, United States
• Pfizer Investigational Site — Walnut Creek, California, United States
• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — ‘Aiea, Hawaii, United States
• Pfizer Investigational Site — Baltimore, Maryland, United States
• Pfizer Investigational Site — New York, New York, United States
• Pfizer Investigational Site — Cleveland, Ohio, United States
• Pfizer Investigational Site — Tel Aviv, Israel, Israel
• Pfizer Investigational Site — Petah Tikva, Israel
• Pfizer Investigational Site — Rehovot, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.